A randomised, double-blind, placebo-controlled, parallel-group study of the standardised extract SHR-5 of the roots of Rhodiola rosea in the treatment of subjects with stress-related fatigue

Planta Medica

Volumn 75, Issue 2, 2009, Pages 105-112

  Olsson, Erik M G ^a,b   Von Schéele, Bo ^b,c   Panossian, Alexander G ^d  

^a UPPSALA UNIVERSITY   (Sweden)

^b PBM Stress Medicine AB   (Sweden)

^c MÄLARDALEN UNIVERSITY   (Sweden)

^d Swedish Herbal Institute   (Sweden)

Author keywords

Clinical trial; Crassulaceae; Fatigue; Rhodiola rosea L.; Stress

Indexed keywords

HYDROCORTISONE; PLACEBO; PSYCHOTROPIC AGENT; RHODIOLA ROSEA EXTRACT; ANTIINFLAMMATORY AGENT; PLANT EXTRACT;

ADULT; ARTICLE; ATTENTION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FATIGUE; HUMAN; MONTGOMERY ASBERG DEPRESSION RATING SCALE; PATIENT COMPLIANCE; PHASE 3 CLINICAL TRIAL; PLANT ROOT; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RHODIOLA; SALIVA LEVEL; SHORT FORM 36; STRESS; SYMPTOM; ANALYSIS OF VARIANCE; BURNOUT; DRUG EFFECT; FEMALE; MALE; MENTAL STRESS; METABOLISM; MIDDLE AGED; PHYTOTHERAPY;

CRASSULACEAE; RHODIOLA ROSEA;

ADULT; ANALYSIS OF VARIANCE; ANTI-INFLAMMATORY AGENTS; ATTENTION; BURNOUT, PROFESSIONAL; DEPRESSION; DOUBLE-BLIND METHOD; FATIGUE; FEMALE; HUMANS; HYDROCORTISONE; MALE; MIDDLE AGED; PHYTOTHERAPY; PLANT EXTRACTS; PLANT ROOTS; RHODIOLA; STRESS, PSYCHOLOGICAL;

EID: 63149169639     PISSN: 00320943     EISSN: 14390221     Source Type: Journal    
DOI: 10.1055/s-0028-1088346     Document Type: Article

References (49)

1. National Board of Health and Welfare. Utmattningssyndrom - Stress-relaterad psykisk ohälsa. 2003-123-218 Stockholm: National Board of Health and Welfare; 2003
2. Linné C. Materia medica - Liber I. de plantis. Stockholm: Lars Salvius; 1749: 168
3. Sparschuch H. Pharmacopoeia Svecia. Stockholm: Holmia; 1775: 39
4. Virey J-J. Racine de roses. Rhodiola rosea L. Traité de pharmacie théorique et pratique,; Vol 1 Paris: Remont-Ferra; 1811: 92
5. Saratikov AS, Krasnov EA. Rhodiola rosea (Golden root). Tomsk: Tomsk University Publishing House; 2004: 292
6. Aksenova RA, Zotova MI, Nekhoda MF, Cherdantsev SG. Comparative characteristics of the stimulants and adaptogenic effects of Rhodiola rosea preparations. In: Saratikov AS, editor. Stimulants of the central nervous system; Vol.2 Tomsk: Tomsk University Publishing House; 1968: 3-12
7. Saratikov AS, Krasnov EE, Chnikina LA, Duvidson LM, Sotova MI, Marina TF et al. Rhodiolosid ein neues Glykosid aus Rhodiola rosea und seine pharmakologischen Eigenschaften. Pharmazie 1968; 23: 392-395
8. Komar VV, Kit SM, Sishchuk LV, Sishchuk VM. Effect of Rhodiola rosea on human mental activity. Pharm J (Kiev) 1981; 36: 62-64
9. Sokolov SYa, Ivashin VK, Zapesochnaya GG, Kurkin VA, Shchavlinskii AN. Studies of neurotropic activity of new compounds isolated from Rhodiola rosea L. Chem Pharm J (Moscow) 1985; 19: 1367-1371
10. Panossian A, Wagner H. Stimulating effects of adaptogens: an overview of clinical trials of adaptogens with particular reference on their efficacy at single dose administration. Phytother Res 2005; 19: 819-838 (Pubitemid 41670526)
11. Müller-Dietz H. Arzneipflanzen in der Sowietunion. Berlin: Berichte des Osteuropa-Instituts an der Freien Universität; 1969: 44, 91-93
12. USSR Ministry of Health. Pharmacopoeia paper 75 - Rhizome and roots of Rhodiola rosea. National pharmacopoeia of the USSR, 11th edition. Moscow: Meditsina; 1990; 2: 317-319 (update No. 2 of 19-05-1999)
13. Estonian Ministry of Health Affairs. Regulation No. 7, Annex 1, 21-101-1998. Tallin: Government of Estonia; 1998
14. Sandberg F. Herbal remedies and herb magic. Stockholm: Det Basta; 1998: 223
15. Mattioli L, Perfumi M. Rhodiola rosea L. extract reduces stress- and CRF-induced anorexia in rats. J Psychopharmacol 2007; 21: 742-750 (Pubitemid 47437914)
16. Petkov VD, Yonkov D, Mosharoff A, Kambourova T, Alova L, Petkov VV et al. Effects of alcohol aqueous extract from Rhodiola rosea L. roots on learning and memory. Acta Physiol Pharmacol Bulg 1986; 12: 3-16
17. Perfumi M, Mattioli L. Adaptogenic and central nervous system effects of single doses of 3% rosavin and 1% rhodioloside Rhodiola rosea L. extract in mice. Phytother Res 2007; 21: 37-43
18. Panossian A, Nikoyan N, Ohanyan N, Hovhannisyan A, Abrahamyan H, Gabrielyan E et al. Comparative study of Rhodiola preparations on behavioral despair of rats. Phytomedicine 2008; 15: 84-91
19. Darbinyan V, Kteyan A, Panossian A, Gabielian E, Wikman G, Wagner H. Rhodiola rosea in stress induced fatigue - a double-blind cross-over study of a standardized extract SHR-5 with a repeated low-dose regimen on the mental performance of healthy physicians during night duty. Phytomedicine 2000; 7: 365-371 (Pubitemid 30781317)
20. Spasov AA, Wikman GK, Mandrikov VB, Mironova IA, Neumoin VV. A double-blind, placebo-controlled pilot study of the stimulating and adaptogenic effect of Rhodiola rosea SHR-5 extract on the fatigue of students caused by stress during an examination period with a repeated low-dose regimen. Phytomedicine 2000; 7: 85-89
21. Shevtsov VA, Zholus BI, Shervaly VI, Volskij VB, Korovin YP, Khristich MP et al. A randomized trial of two different doses of a SHR-5 Rhodiola rosea extract versus placebo and control of capacity for mental work. Phytomedicine 2003; 10: 95-105
22. Grossi G, Perski A, Ekstedt M, Johansson T, Lindstrom M, Holm K. The morning salivary cortisol response in burnout. J Psychosom Res 2005; 59: 103-111 (Pubitemid 41375981)
23. World Medical Association. Declaration of Helsinki: ethical principles for medical research involving human subjects. J Postgrad Med 2002; 48: 206-208
24. World Health Organisation. ICD-10 - International statistical classification of diseases and related health problems. Arlington: American Psychiatric Publishing; 1992
25. Pines A, Aronson E, Kafry D. Burnout: from tedium to personal growth. New York: Free Press; 1981
26. International Conference on Harmonisation. ICH Topic Q2B Validation of Analytical Procedures: Methodology, Step 4, Consensus Guidelines, 6 November, 1996 [www.emea.eu.int/pdfs/human/ich/028195en.pdf]
27. International Organisation for Standardisation. EN ISO/IEC 17 025:2001 Standard Accreditation Requirements for QC Laboratories Operating under the GxP Compliance Requirements 2001 [http://www.effichem.com]
28. Conners CK. Conners' continuous performance test II: Computer program for Windows - Technical guide and software manual. Toronto: Multi-Health Systems; 2003
29. Hallsten L, Bellaagh K, Gustafsson K. Utbränning i Sverige - en populationsstudie. Arbete och Hälsa: Arbetslivsinstitutet; 2002
30. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979; 134: 382-389 (Pubitemid 9136500)
31. Sullivan M, Karlsson J, Ware J. The Swedish SF-36 health survey - I. Evaluation of data quality, scaling assumptions, reliability and construct validity across general populations in Sweden. Soc Sci Med 1995; 41: 1349-1358
32. Persson L-O, Karlsson J, Bengtsson C, Steen B, Sullivan M. The Swedish SF-36 health survey - II. Evaluation of clinical validity: Results from population studies of elderly and women in Gothenburg. J Clin Epidemiol 1998; 51: 1095-1103 (Pubitemid 28527165)
33. Sullivan M, Karlsson J. The Swedish SF-36 health survey - III. Evaluation of criterion-based validity: Results from normative population. J Clin Epidemiol 1998; 51: 1105-1113 (Pubitemid 28527166)
34. Pruessner JC, Hellhammer DH, Kirschbaum C. Burnout, perceived stress, and cortisol responses to awakening. Psychosom Med 1999; 61: 197-204 (Pubitemid 29168650)
35. de Vente W, Olff M, van Amsterdam JG, Kamphuis JH, Emmelkamp PM. Physiological differences between burnout patients and healthy controls: blood pressure, heart rate, and cortisol responses. Occup Environ Med 2003; 601: i54-61
36. Levin ED, Conners CK, Silva D, Canu W, March J. Effects of chronic nicotine and methylphenidate in adults with attention deficit/hyperactivity disorder. Exp Clin Psychopharmacol 2001; 9: 83-90 (Pubitemid 32852217)
37. Vercoulen JH, Bazelmans E, Swanink CM, Galama JM, Fennis JF, van der Meer JW et al. Evaluating neuropsychological impairment in chronic fatigue syndrome. J Clin Exp Neuropsychol 1998; 20: 144-156 (Pubitemid 28451693)
38. StatSoft. STATISTICA (data analysis software system). Tulsa: StatSoft; 2004
39. rd scientific conference of physiologists. Tomsk: Biochemists and Pharmacologists of Western Siberia; 1965: 298-299
40. Marina TF, Mikhaleva LK, Suslov NI. Comparative effects of para-tyrosol and Rhodiola extract on the central nervous system. Proceedings of a Joint Plenary Session of Pathophysiologists and Pharmacologists of Siberia and the Far East on Mechanisms of the Development of Pathological Processes. Kemerovo: Kemerovo State University Press; 1994: 66-68
41. Munk A. Corticosteroids and stress. In: Fink G, editor. Encyclopedia of stress; Vol 1 San Diego: Academic Press; 2000: 570-577
42. Young AH. Cortisol in mood disorders. Stress 2004; 7: 205-208
43. Panossian AG. Adaptogens: Tonic herbs for fatigue and stress. Altern Compliment Therapies 2003; 9: 327-332
44. Panossian A, Hambartsumyan M, Hovanissian A, Gabrielyan E, Wikman G. The adaptogens Rhodiola and Schizandra modify the response to immobilization stress in rabbits by suppressing the increase of phosphorylated stress-activated protein kinase, nitric oxide and cortisol. Drug Target Insights 2007; 1: 39-54 Available at http://la-press.-com/article-id = 260. Accessed June 26, 2008
45. Kirschbaum C, Hellhammer DH. Salivary cortisol in psychoneuroendocrine research: recent developments and applications. Psychoneuroendocrinology 1994; 19: 313-333 (Pubitemid 24150545)
46. Schmidt-Reinwald A, Pruessner JC, Hellhammer DH, Federenko I, Rohleder N, Schürmeyer TH et al. The cortisol response to awakening in relation to different challenge tests and a 12-hour cortisol rhythm. Life Sci 1999; 64: 1653-1660 (Pubitemid 29185346)
47. Holsboer F. The corticosteroid receptor hypothesis of depression. Neuropsychopharmacology 2000; 23: 477-501
48. Darbinyan V, Aslanyan G, Amroyan E, Gabrielyan E, Malmström C, Panossian A. Clinical trial of Rhodiola rosea L. extract SHR-5 in the treatment of mild to moderate depression. Nord J Psychiatry 2007; 61: 343-348
49. Herbert J, Goodyer IM, Grossman AB, Hastings MH, de Kloet ER, Lightman SL et al. Do corticosteroids damage the brain? J Neuroendocrinol 2006; 18: 393-411